Design, synthesis and bioactivity evaluation of novel quinazoline based KRASG12C inhibitors. (18th February 2022)

• Record Type: Journal Article
• Authors: Liu, Qingxu; Li, Yan; Zhi, Ying; Liu, Bo; Sun, Jingyong
• Is Part Of: New journal of chemistry. Volume 46:Number 10(2022)
• Page Start: 4827
• Page End: 4836
• Publication Date: 2022-02-18
• Subjects: Chemistry -- Periodicals; Chimie -- Périodiques; 540
• DOI: 10.1039/d1nj06226c
• Languages: English
• ISSNs: 1144-0546

Abstract

Abstract : KRAS is a member of the RAS gene family, which is involved in the regulation of human life activitie. A series of new quinazoline compounds were designed and synthesized, and their KRAS inhibition ability was verified by activity assay. Abstract : KRAS is a member of the RAS gene family, which is involved in the regulation of human life activities. KRAS G12C mutation is distributed in many tumors and has been the focus of attention. In our study, we analyzed the binding of BAY-293 to KRAS protein using molecular docking technology. We designed and synthesized 20 compounds and tested their bioactivity. At the same time, we found that compound 8P (IC50 = 2.6 ± 1.2 μM) had good inhibitory activity against the A549 cell line and compound 8e had a good inhibitory effect on the McF-7 cell line with IC50 = 5.5 ± 0.3 μM.